Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets

Cancer Immunology, Immunotherapy

Volumn 64, Issue 11, 2015, Pages 1461-1473

  Sköld, Annette E ^a,b   van Beek, Jasper J P ^a   Sittig, Simone P ^a   Bakdash, Ghaith ^a   Tel, Jurjen ^a   Schreibelt, Gerty ^a   de Vries, I Jolanda M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvants; GMP; Immunotherapy; mDC; pDC; TLR

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; PROTAMINE; PROTEIN; RIBONUCLEASE; SINGLE STRANDED RNA; SODIUM CHLORIDE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; IMMUNOLOGICAL ADJUVANT; RNA; TOLL LIKE RECEPTOR;

ACIDIFICATION; ANTIGEN PRESENTATION; ARTICLE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); DENDRITIC CELL; DOSE RESPONSE; ENDOSOME; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; PROTEIN SECRETION; RNA STABILITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; CLASSIFICATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSOMES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PROTAMINES; RNA; RNA STABILITY; SODIUM CHLORIDE; TOLL-LIKE RECEPTORS;

EID: 84945492647     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1746-9     Document Type: Article

References (42)

1. Boltjes A, van Wijk F (2014) Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol 5:131. doi:10.3389/fimmu.2014.00131
2. Palucka K, Banchereau J (2013) Human dendritic cell subsets in vaccination. Curr Opin Immunol 25(3):396–402. doi:10.1016/j.coi.2013.05.001
3. Joffre O, Nolte MA, Sporri R, Reis e Sousa C (2009) Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227(1):234–247. doi:10.1111/j.1600-065X.2008.00718.x
4. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227(1):221–233. doi:10.1111/j.1600-065X.2008.00731.x
5. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373–384. doi:10.1038/ni.1863
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475–480. doi:10.1038/nm1039
7. Nestle FO, Farkas A, Conrad C (2005) Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 17(2):163–169. doi:10.1016/j.coi.2005.02.003
8. Wimmers F, Schreibelt G, Sköld AE, Figdor CG, De Vries IJ (2014) Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 5:165. doi:10.3389/fimmu.2014.00165
9. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M, Winkels G, Coulie PG, Punt CJ, Figdor CG, de Vries IJ (2013) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 73(3):1063–1075. doi:10.1158/0008-5472.CAN-12-2583
10. Mazzoni A, Segal DM (2004) Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 75(5):721–730. doi:10.1189/jlb.1003482
11. de Jong EC, Smits HH, Kapsenberg ML (2005) Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 26(3):289–307. doi:10.1007/s00281-004-0167-1
12. Liu YJ (2001) Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106(3):259–262
13. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, de Vries IJ (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59(10):1573–1582. doi:10.1007/s00262-010-0833-1
14. Sköld AE, Hasan M, Vargas L, Saidi H, Bosquet N, Le Grand R, Smith CI, Spetz AL (2012) Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 120(4):768–777. doi:10.1182/blood-2011-12-397778
15. Bakdash G, Schreurs I, Schreibelt G, Tel J (2014) Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Rev Clin Immunol 10(7):915–926. doi:10.1586/1744666X.2014.912561
16. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663):1526–1529. doi:10.1126/science.1093620
17. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, Jung G, Rammensee HG, Pascolo S (2004) Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 34(2):537–547. doi:10.1002/eji.200324198
18. Vasilakos JP, Tomai MA (2013) The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 12(7):809–819. doi:10.1586/14760584.2013.811208
19. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, Jarrossay D, Wagner H, Jung G, Rammensee HG, Hoerr I, Pascolo S (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35(5):1557–1566. doi:10.1002/eji.200425656
20. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, Kallen KJ (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34(1):1–15. doi:10.1097/CJI.0b013e3181f7dbe8
21. Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30(1):1–7. doi:10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#
22. Schaft N, Dorrie J, Muller I, Beck V, Baumann S, Schunder T, Kampgen E, Schuler G (2006) A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 55(9):1132–1141. doi:10.1007/s00262-005-0098-2
23. Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ (2010) Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116(4):564–574. doi:10.1182/blood-2009-11-251884
24. Billiau A, Buckler CE, Dianzani F, Uhlendorf C, Baron S (1969) Induction of the interferon mechanism by single-stranded RNA: potentiation by polybasic substances. Proc Soc Exp Biol Med 132(2):790–796
25. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP (2008) Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29(24–25):3477–3496. doi:10.1016/j.biomaterials.2008.04.036
26. Rettig L, Haen SP, Bittermann AG, von Boehmer L, Curioni A, Kramer SD, Knuth A, Pascolo S (2010) Particle size and activation threshold: a new dimension of danger signaling. Blood 115(22):4533–4541. doi:10.1182/blood-2009-11-247817
27. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ (2013) Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121(3):459–467. doi:10.1182/blood-2012-06-435644
28. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5(12):1219–1226. doi:10.1038/ni1141
29. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70(22):9031–9040. doi:10.1158/0008-5472.CAN-10-0699
30. Hontelez S, Ansems M, Karthaus N, Zuidscherwoude M, Looman MW, Triantis V, Adema GJ (2012) Dendritic cell-specific transcript: dendritic cell marker and regulator of TLR-induced cytokine production. J Immunol 189(1):138–145. doi:10.4049/jimmunol.1103709
31. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB (2003) Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 100(11):6646–6651. doi:10.1073/pnas.0631696100
32. de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG (2011) Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol 48(6–7):810–817. doi:10.1016/j.molimm.2010.12.022
33. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9(14):5091–5100
34. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M (2009) Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 206(9):1983–1994. doi:10.1084/jem.20090480
35. Yoo E, Salunke DB, Sil D, Guo X, Salyer AC, Hermanson AR, Kumar M, Malladi SS, Balakrishna R, Thompson WH, Tanji H, Ohto U, Shimizu T, David SA (2014) Determinants of activity at human toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds. J Med Chem 57(19):7955–7970. doi:10.1021/jm500744f
36. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP (2005) Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174(3):1259–1268
37. Ishii N, Funami K, Tatematsu M, Seya T, Matsumoto M (2014) Endosomal localization of TLR8 confers distinctive proteolytic processing on human myeloid cells. J Immunol 193(10):5118–5128. doi:10.4049/jimmunol.1401375
38. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 60(2):249–260. doi:10.1007/s00262-010-0942-x
39. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, Moretta A, Thiel A (2005) Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol 35(8):2452–2458. doi:10.1002/eji.200526069
40. van Beek JJ, Wimmers F, Hato SV, de Vries IJ, Sköld AE (2014) Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination. Crit Rev Immunol 34(6):517–536
41. Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, Liu YJ, Lifson JD, Littman DR, Bhardwaj N (2004) Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 78(10):5223–5232
42. Starbeck-Miller GR, Xue HH, Harty JT (2014) IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J Exp Med 211(1):105–120. doi:10.1084/jem.20130901